Autolus Therapeutics plc (AUTL)

6.44 -0.10 (-1.53%) At close: 4:00PM EST

Autolus Therapeutics plc

Forest House
58 Wood Lane White City
London W12 7RZ
United Kingdom
44 20 3829 6230
http://www.autolus.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 290

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Christian Martin Itin	Chairman & CEO	N/A	N/A	1964
Dr. Martin Pulé	Founder, Sr. VP, Chief Scientific Officer & Director	N/A	N/A	1972
Mr. Andrew J. Oakley	CFO & Sr. VP	N/A	N/A	1962
Mr. Christopher Vann	Sr. VP & COO	N/A	N/A	1965
Mr. David Brochu	Chief Technical Officer	N/A	N/A	1958
Mr. Matthias Alder	Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.	N/A	N/A	1965
Dr. Muhammad Al-Hajj Ph.D.	Sr. VP of Translational Sciences	N/A	N/A	1971
Dr. Lucinda Crabtree Ph.D.	VP of IR & Corp. Communications	N/A	N/A	N/A
Mr. Vishal Mehta	VP & Head of Clinical Operations	N/A	N/A	N/A
Dr. Nushmia Khokhar	Sr. VP of Clinical Devel.	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Corporate Governance

Autolus Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.